Abstract: Method of inhibiting proliferation of cells using vpr protein or nucleotide sequences that encode vpr are disclosed. Method of preventing lymphocyte activation using vpr protein or nucleotide sequences that encode vpr are disclosed. Methods of treating an individual diagnosed with or suspected of suffering from autoimmune disease, diseases characterized by proliferating cells and graft versus host disease by administering vpr protein or a functional fragment thereof, or a nucleic acid molecule that comprises a nucleotide sequence that encodes vpr protein or a functional fragment thereof are disclosed. Conjugated compositions for delivery of active agents to the nucleus of cells are disclosed.

Abstract: Disclosed are recombinant baculovirus expressing the gag, gp70, and gp85 genes of feline leukemia virus. Also disclosed are vaccines based on protein expressed from these recombinants. Also disclosed is a combined mucosal/parenteral inoculation method.

Abstract: Recombinant fusion proteins which comprise a biologically active polypeptide portion and metal chelating peptide are disclosed. The fusion proteins contain metal chelating peptides which have at least three and preferably six alternating histidine residues. Fusion proteins which contain metal chelating peptides that are substrates for dipeptidylpeptidase I are also disclosed. Additionally, a method of obtaining desired polypeptides by producing recombinant fusion proteins and purifying them with immobilized metal ions is disclosed. A kit for purifying desired polypeptides is also disclosed.

Abstract: This invention encompasses novel chimeric glycoproteins which are useful for preparing virus specific immune responses against human parainfluenza virus type 3, PIV3. Host cells transformed with structural genes coding for the glycoproteins, expression and replication plasmids containing the structural genes, vaccines made from the glycoproteins and methods for protecting humans by inoculation with said vaccines are also part of this invention.

Abstract: This invention encompasses DNA compositions encoding novel chimeric glycoproteins which are useful for preparing virus specific immune responses against human respiratory syncytial virus. The DNA compositions include structural genes coding for the glycoproteins and expression and replication plasmids containing the structural genes. Host cells transformed with the above DNA compositions, vaccines made from the glycoproteins and methods for protecting humans by inoculation with said vaccines are also part of this invention.

Abstract: A method for identifying compounds that inhibit HIV protease is disclosed. A substrate that comprises an HIV protease cleavage site is combined with HIV protease and test compounds. Cleavage of the substrate indicates protease activity and can be detected using antibodies against a cleavage product which do not cross react with uncleaved substrate. A method of detecting the presence of anti-HIV protease antibodies in a sample is also disclosed. A substrate is combined with the sample and HIV protease. Detection of substrate cleavage indicates that the protease is active and that there is an absence of neutralizing anti-HIV protease antibodies.

Abstract: This invention encompasses novel chimeric glycoproteins which are useful for preparing virus specific immune responses against human parainfluenza virus type 3, PIV3. Host cells transformed with structural genes coding for the glycoproteins, expression and replication plasmids containing the structural genes, vaccines made from the glycoproteins and methods for protecting humans by inoculation with said vaccines are also part of this invention.

Abstract: A stable transformed HEK 293 cell comprising a functional GABA.sub.A receptor that comprises a GABA.sub.A receptor .alpha. subunit, a GABA.sub.A receptor .beta. subunit and a GABA.sub.A receptor .gamma. subunit is disclosed.

Abstract: A method for identifying compounds useful for treating patients with amyloidosis is disclosed. Compounds are screened according to the present invention to determine their ability to modulate the affinity between amyloid protein and proteins of the extracellular matrix.

Abstract: The present invention relates to a recombinant multigene comprising a plurality of structural genes and a plurality of DNA sequences which encode peptide linkers. In the present invention, one of the structural genes encodes a protease, the DNA sequences encoding the peptide linkers are adjacent to the DNA sequences which encode the structural genes and the peptide linkers contain an amino acid sequence which the protease recognizes as a proteolytic cleavage site. The present invention additionally relates to transgenic plants which contain such a recombinant multigene transgene, host cells transformed with such a recombinant multigene, and transgenic animals which contain such a recombinant multigene transgene. Furthermore, the present invention relates to a method of producing a plurality of polypeptides in a host by incorporating and expressing in the host a such recombinant multigene.

Abstract: This invention discloses compositions of DNA and proteins that are useful for preparing vaccines against human respiratory syncytial virus [HRSV]. The DNA compositions include structural genes coding for native structural viral proteins and immunogenic fragments of these proteins. Host cells transformed with the above DNA compositions are also disclosed. Vaccines made from the native structural viral proteins or immunogenic fragments are also disclosed as well as methods for protecting humans by inoculation with these vaccines.

Abstract: Provided are a virus vaccine, comprising a properly incapacitated virus lacking an antigen of the wild-type virus which is useful for serologically distinguished between vaccinated and infected animals, methods for distinguishing between vaccinated and infected animals and multivalent vaccines.

Abstract: The present invention relates to the use of the polyadenylation signal from the gene for bovine growth hormone to achieve a high level of expression of peptides in eukaryotic cells. Accordingly, the present invention provides a recombinant DNA compound comprising: a first nucleotide sequence which contains a promoter capable of initiating transcription of a gene; a second nucleotide sequence which encodes a gene for a polypeptide other than bovine growth hormone, including genomic and other intron containing forms thereof; a third nucleotide sequence which contains a bovine growth hormone polyadenylation signal; and a fourth nucleotide sequence which optionally contains a selectable marker. The first, second and third sequences are operably linked in sequence to form a functional genetic unit capable of being expressed. The fourth sequence, which is optionally provided, is useful for determining whether or not the DNA of the present invention has been incorporated into a living cell.

Abstract: This invention discloses human tissue plasminogen activator (TPA) analogs. The analogs are TPA-like molecules that have had the native domain regions either rearranged, delected, added or a combination thereof. The analogs are the product of the expression of recombinant DNA also described herein. Additonally, the present invention described replication and expression plasmids containing the TPA-coding DNA sequences described above and suitable host microorganisms that are capable of expressing the TPA analogs after becoming transformed with an appropriate plasmid.

Abstract: A method for identifying compounds useful as antiparasitic drugs is disclosed. Deficient microorganisms are complemented with homologous metabolic enzyme genes. The metabolic enzyme is the drug target. In addition, recombinant DNA molecules comprising helminthic PFK and PEPCK genes are disclosed.

Abstract: Provided are hybridomas for producing monoclonal antibodies against human prostate secretory protein (PSP15), anti-PSP15 monoclonal antibodies, fragments and derivatives thereof, and methods for their use. The antibodies are monospecific, bind to protein A and are of the IgM class of immunoglobulins. The monoclonal antibodies are useful as basic diagnostics for detecting human prostate cancer cells.